BridgeMD
New treatment option for Hypertrophic Cardiomyopathy (HCM)
Official title Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
ClinicalTrials.gov ID: NCT07600177
What this study is testing
What is Aficamten?
Aficamten is an investigational medicine, being studied as a potential treatment for hypertrophic cardiomyopathy (hcm).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 90
You may be able to join if
- Documented history of oHCM with documented resting and/or Valsalva LVOT obstruction ≥ 50 mmHg who are currently receiving mavacamten commercially.
- Echo-derived LVEF ≥55% on mavacamten at the time of enrollment.
- Patient willing to consent for the study and undergo the study procedures.
You likely can't join if
- Severe aortic stenosis or sub-aortic obstruction
- Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM (eg, Noonan syndrome, Fabry disease, amyloidosis).
- History of LVEF \<30%.
- Paroxysmal atrial fibrillation (AF) with documented episode within 3 months.
- Atrial fibrillation (paroxysmal or permanent) not on systemic anticoagulation.
- Documented history of current obstructive coronary artery disease (\> 70% stenosis in one or more epicardial coronary arteries) or documented history...
The study team makes the final eligibility decision.
Where it's taking place
- Kansas City, Missouri, United States
- Portland, Oregon, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kansas City, Missouri, United States; Portland, Oregon, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.